Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Purchases 11,500 Shares of Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Celldex Therapeutics Price Performance

CLDX stock opened at $25.74 on Friday. The stock’s 50 day simple moving average is $32.65 and its 200 day simple moving average is $35.60. Celldex Therapeutics, Inc. has a 12-month low of $24.43 and a 12-month high of $53.18.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CLDX shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Thursday, November 7th. Finally, Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $62.25.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV lifted its position in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Celldex Therapeutics in the second quarter worth about $76,000. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the first quarter worth about $147,000. CANADA LIFE ASSURANCE Co boosted its stake in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the period. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 1,582 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.